All In Biotech

Drug Trial Radar · NCT07207811

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

CLEOPATTRA: Effects of NNC6019-0001 Versus Placebo on Cardiovascular Outcomes in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,280 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,280

Planned (sponsor's estimate)

Start

Oct 2, 2025

Primary completion

Jun 29, 2029

Study completion Jun 29, 2029

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Oct 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy (ATTR-CM), which affects the heart. Participants will either receive NNC6019-0001 or a placebo (a treatment with no active medicine), and which one they get is decided by chance. Everyone in the study will continue receiving their usual heart treatments as recommended by their doctor.

Conditions

  • Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Interventions

  • NNC6019-0001Drug

    NNC6019-0001 will be administered IV.

  • Placebo (NNC6019-0001)Drug

    Placebo matched to NNC6019-0001 will be administered IV.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite Outcome of cardiovascular (CV) deaths and recurrent CV events (CV hospitalisations and urgent heart failure [HF] visits)Time frame: From baseline (week 0) to end of study (EOS) (up to approximately 4 years)

Locations

299 sites in 20 countries. Site status is shown where the registry gives one.

  • Mayo Clinic in Arizona

    Phoenix, Arizona · Recruiting

  • University of California San Diego (UCSD) - Sulpizio Cardiovascular Center (SCVC)

    La Jolla, California · Recruiting

  • Keck School of Medicine USC - Healthcare Consultation Center 2 (HCCII)

    Los Angeles, California · Recruiting

  • Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute

    Los Angeles, California · Not yet recruiting

  • UCI Medical Center

    Orange, California · Recruiting

  • Profound Research LLC at Southern California Heart Specialists

    Pasadena, California · Recruiting

  • University of California, San Francisco Medical Center

    San Francisco, California · Recruiting

  • NorthBay Clinical Research

    Santa Rosa, California · Recruiting

  • Lucile Packard Children's Hospital

    Stanford, California · Recruiting

  • Yale University School of Medicine

    New Haven, Connecticut · Recruiting

  • MedStar Heart & Vascular Institute (MHVI) - MedStar Washington Hospital Center

    Washington D.C., District of Columbia · Recruiting

  • UF Health Heart and Vascular Hospital

    Gainesville, Florida · Recruiting

  • Northeast Georgia Heart Center, Pc (Nghc)

    Gainesville, Georgia · Recruiting

  • The Queen's Medical Center

    Honolulu, Hawaii · Recruiting

  • Northwestern University Clinical and Translational Sciences Institute

    Chicago, Illinois · Recruiting

  • The University of Chicago Medicine

    Chicago, Illinois · Recruiting

  • Endeavor Health - Glenbrook Hospital

    Glenview, Illinois · Recruiting

  • Indiana University (IU) Health - Methodist Professional Center II

    Indianapolis, Indiana · Recruiting

  • LCMC - LSU University Medical Center New Orleans LCMC Center

    New Orleans, Louisiana · Recruiting

  • University of Maryland Medical Center (UMMC) - Children's Hospital (UMCH)

    Baltimore, Maryland · Recruiting

  • John Hopkins Medicine

    Baltimore, Maryland · Recruiting

  • Tufts Medical Center

    Boston, Massachusetts · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • University of Michigan Health System

    Ann Arbor, Michigan · Recruiting

  • Henry Ford Health

    Detroit, Michigan · Recruiting

  • Profound Research

    Farmington Hills, Michigan · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Cardiology Associates Research, LLc

    Tupelo, Mississippi · Completed

  • Saint Luke's Hospital of Kansas City

    Kansas City, Missouri · Recruiting

  • Saint Louis University

    St Louis, Missouri · Not yet recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • North Shore University Hospital, Northwell Health

    Manhasset, New York · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • Weill Medical College Of Cornell University

    New York, New York · Recruiting

  • Mount Sinai Medical Center

    New York, New York · Recruiting

  • Columbia University Medical Center

    New York, New York · Recruiting

  • Laurelton Heart Specialist, PC

    Rosedale, New York · Recruiting

  • Yeshiva University - Albert Einstein College of Medicine - Montefiore Medical Center (MMC)

    The Bronx, New York · Recruiting

  • Duke University Health System

    Durham, North Carolina · Recruiting

Showing 40 of 299 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.